Aurobindo Pharma has moved higher by 3% at Rs 127, extending its previous two day’s rally after the company said it had received final approvals from the US drug regulator -- US Food & Drug Administration (USFDA) -- to manufacture and market anti-hypertension drug Amlodipine Besylate and Benazepril Hydrochloride capsules in various strengths.
“The annual sales of Amlodipine Besylate and Benazepril Hydrochloride capsules is approximately $500 million for the twelve months ending March 2012, according to IMS Data,” Aurobindo Pharma said in a filing.
With the latest approval, Aurobindo now has a total of 158 ANDA approvals from the US drug regulator, of which 133 are final approvals, including one from Aurolife Pharma LLC, and 25 are tentative approvals, it added.
The stock opened at Rs 124 on the National Stock Exchange and has seen a combined 532,436 shares changing hands on the counter so far on both the exchanges.